Primary efficacy endpoints , reflecting differing regional regulatory requirements , included change from baseline in worse eye intraocular pressure ( IOP ) in the per-protocol population at week 12 , and the average eye IOP at weeks 2 , 6 and 12 in the intent-to-treat population .